Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics dev...
MuBase offers a user-friendly experience while searching a large collection of model data, including tumor pathology, genomic characterization, and in vivo pharmacology data with standard of care a...
CrownBio’s models are unparalleled in their translatability and enable clinically translatable evaluation of therapeutics that target not only kidney complications, but also hyperglycemia in diabet...
Thanks to the new XenoBase feature, users will now be able to directly search and interact with dose response curves and IC50 data for over 290 cell lines.
CrownBio will present new data on the development of preclinical solutions for NASH research, a therapeutic area with a high unmet need of models for pharmacological evaluation.
CrownBio’s ALL and AML patient-derived xenograft (PDX) models of different leukemia subtypes are unique in the commercial world, in that they are validated, stable models with typical leukemia symp...
OmniScreen™ will be run on a cycled schedule every three months, allowing clients to select from three panels of cell lines that are most suitable for their needs.
CrownBio has made the stable cell lines available for delivery, ready to be shipped overnight for next day delivery in the United States and within one week internationally.
